Ukr.Biochem.J. 2023; Volume 95, Issue 5, Sep-Oct, pp. 31-40

doi: https://doi.org/10.15407/ubj95.05.031

Assessment of urinary podocalyxin as a biomarker of early diagnosis of hypertensive nephropathy

02.11.2023   Uncategorized   No comments

I. Kostovska*, K. Tosheska-Trajkovska, D. Labudovic,
S. Cekovska, O. Kostovski, G. Spasovski

Faculty of Medicine, Ss. Cyril and Methodius University in Skopje, North Macedonia;
*e-mail: irenakostovska22@yahoo.com

Received: 31 August 2023; Revised: 28 September 2023;
Accepted: 27 October 2023; Available on-line: 06 November 2023

Chronically high blood pressure-related kidney injury is known as hypertensive nephropathy (HN). Podocyte damage in the pathogenesis of this disease can result in the release of the sialoglycoprotein podocalyxin into the urine, so podocalyxin may be useful in the early diagnosis of HN. The purpose of the study was to examine the relationships between urine podocalyxin level and clinical and biochemical parameters in individuals with HN and to assess the diagnostic utility of urinary podocalyxin as an early marker of HN. Participants (114 individuals) were enrolled in this cross-sectional study, including 30 healthy controls and 84 patients with clinically proven chronic hypertension (CH). Biochemical tests were performed on the blood samples. Urinary microalbumin and creatinine levels were measured using immunoturbidimetric and spectrophotometric methods, respectively; urinary podocalyxin level was estimated with ELISA. All CH patients were classified into subgroups according to urine microalbumin/creatinine ratio (UM/CR) and the stage of chronic kidney disease (CKD). The results obtained showed that urinary podocalyxin level was significantly increased in both UM/CR and CKD staging subgroups compared with the healthy control group. A gradual increase in urinary podocalyxin level with CKD stage, especially in IV and V stages, and the higher sensitivi­ty of urinary podocalyxin as compared to UM/CR ratio in early detection of HN was demonstrated. It was concluded that urinary podocalyxin may be an important and highly sensitive marker for early diagnosis of hypertensive nephropathy in patients with chronic hypertension.

Keywords: , , , , ,

References:

  1. Costantino VV, Gil Lorenzo AF, Bocanegra V, Vallés PG. Molecular Mechanisms of Hypertensive Nephropathy: Renoprotective Effect of Losartan through Hsp70. Cells. 2021;10(11):3146. PubMed, PubMedCentral, CrossRef
  2. Carriazo S, Vanessa Perez-Gomez M, Ortiz A. Hypertensive nephropathy: a major roadblock hindering the advance of precision nephrology. Clin Kidney J. 2020;13(4):504-509. PubMed, PubMedCentral, CrossRef
  3. Choi Y, Jacobs DR Jr, Shroff GR, Kramer H, Chang AR, Duprez DA. Progression of Chronic Kidney Disease Risk Categories and Risk of Cardiovascular Disease and Total Mortality: Coronary Artery Risk Development in Young Adults Cohort. J Am Heart Assoc. 2022;11(21):e026685. PubMed, PubMedCentral, CrossRef
  4. Prasad RM, Bali A, Tikaria R. Microalbuminuria. [Updated 2023 May 30]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023. Available from: https://www.ncbi.nlm.nih.gov/books/NBK563255/
  5. Sun D, Wang J, Yao L, Li Z, Ohno S. Research Progress in Acute Hypertensive Renal Injury by ” in Vivo Cryotechnique”. J Transl Int Med. 2019;7(4):132-136. PubMed, PubMedCentral, CrossRef
  6. Sun D, Wang JJ, Wang W, Wang J, Wang LN, Yao L, Sun YH, Li ZL. Human podocyte injury in the early course of hypertensive renal injury. World J Clin Cases. 2019;7(22):3698-3710. PubMed, PubMedCentral, CrossRef
  7. Seccia TM, Caroccia B, Calò LA. Hypertensive nephropathy. Moving from classic to emerging pathogenetic mechanisms. J Hypertens. 2017;35(2):205-212. PubMed, CrossRef
  8. Le Tran N, Wang Y, Nie G. Podocalyxin in Normal Tissue and Epithelial Cancer. Cancers (Basel). 2021;13(12):2863. PubMed, PubMedCentral, CrossRef
  9. Chapter 1: Definition and classification of CKD. Kidney Int Suppl. 2013;3(1):19-62. PubMed, PubMedCentral, CrossRef
  10. Inker LA, Astor BC, Fox CH, Isakova T, Lash JP, Peralta CA, Kurella Tamura M, Feldman HI. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD. Am J Kidney Dis. 2014;63(5):713-735. PubMed, CrossRef
  11. Cocroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31-41. PubMed, CrossRef
  12. Habibzadeh F, Habibzadeh P, Yadollahie M. On determining the most appropriate test cut-off value: the case of tests with continuous results. Biochem Med (Zagreb). 2016;26(3):297-307. PubMed, PubMedCentral, CrossRef
  13. Qaseem A, Hopkins RH Jr, Sweet DE, Starkey M, Shekelle P. Screening, monitoring, and treatment of stage 1 to 3 chronic kidney disease: A clinical practice guideline from the American College of Physicians. Ann Intern Med. 2013;159(12):835-847. PubMed, CrossRef
  14. Koroshi A. Microalbuminuria, is it so important? Hippokratia. 2007;11(3):105-107. PubMed, PubMedCentral
  15. Kretzler M, Koeppen-Hagemann I, Kriz W. Podocyte damage is a critical step in the development of glomerulosclerosis in the uninephrectomised-desoxycorticosterone hypertensive rat. Virchows Arch. 1994;425(2):181-193. PubMed, CrossRef
  16. Kato T, Mizuguchi N, Ito A. Characteristics of podocyte injury in malignant hypertensive nephropathy of rats (MSHRSP/Kpo strain). Biomed Res. 2015;36(5):313-321. PubMed, PubMedCentral, CrossRef
  17. Mizdrak M, Kumrić M, Kurir TT, Božić J. Emerging Biomarkers for Early Detection of Chronic Kidney Disease. J Pers Med. 2022;12(4):548. PubMed, PubMedCentral, CrossRef
Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License.